Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer

Genes and Development

Volumn 20, Issue 22, 2006, Pages 3130-3146

  Bardeesy, Nabeel ^a   Cheng, Kuang Hung ^a   Berger, Justin H ^a   Chu, Gerald C ^b   Pahler, Jessica ^c   Olson, Peter ^a,c   Hezel, Aram F ^a,b   Horner, James ^b   Lauwers, Gregory Y ^d   Hanahan, Douglas ^c   DePinho, Ronald A ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Epithelial to mesenchymal transition mouse models; Pancreatic cancer; Smad4; TGF

Indexed keywords

ARF PROTEIN; BONE MORPHOGENETIC PROTEIN 4; BROXURIDINE; CRE RECOMBINASE; PROTEIN P16INK4A; SMAD4 PROTEIN; TRANSCRIPTION FACTOR PDX 1; TRANSFORMING GROWTH FACTOR BETA;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIUM CELL; GENE DELETION; GENE LOCUS; GENE MUTATION; HISTOPATHOLOGY; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MESENCHYME; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE K RAS; PANCREAS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS DUCT; PHENOTYPE; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ALLELES; ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL DIFFERENTIATION; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; GENE DELETION; GENES, RAS; MICE; PANCREAS; PANCREATIC NEOPLASMS; PHENOTYPE; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 33751251034     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.1478706     Document Type: Article

References (60)

1. Adsay, N.V., Merati, K., Basturk, O., Iacobuzio-Donahue, C., Levi, E., Cheng, J.D., Sarkar, F.H., Hruban, R.H., and Klimstra, D.S. 2004. Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: Delineation of an 'intestinal' pathway of carcinogenesis in the pancreas. Am. J. Surg. Pathol. 28: 839-848.
2. Aguirre, A.J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D.A., Horner, J., Redston, M.S., and DePinho, R.A. 2003. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes & Dev. 17: 3112-3126.
3. Apte, M.V., Park, S., Phillips, P.A., Santucci, N., Goldstein, D., Kumar, R.K., Ramm, G.A., Buchler, M., Friess, H., McCarroll, J.A., et al. 2004. Desmoplastic reaction in pancreatic cancer: Role of pancreatic stellate cells. Pancreas 29: 179-187.
4. Bardeesy, N., Morgan, J., Sinha, M., Signoretti, S., Srivastava, S., Loda, M., Merlino, G., and DePinho, R.A. 2002a. Obligate roles for p16(Ink4a) and p19(Arf)-p53 in the suppression of murine pancreatic neoplasia. Mol. Cell. Biol. 22: 635-643.
5. Bardeesy, N., Sinha, M., Hezel, A.F., Signoretti, S., Hathaway, N.A., Sharpless, N.E., Loda, M., Carrasco, D.R., and DePinho, R.A. 2002b. Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature 419: 162-167.
6. Bardeesy, N., Aguirre, A.J., Chu, G.C., Cheng, K.H., Lopez, L.V., Hezel, A.F., Feng, B., Brennan, C., Weissleder, R., Mahmood, U., et al. 2006. Both p16Ink4a and the p19Arf-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc. Natl. Acad. Sci. 103: 5947-5952.
7. Biankin, A.V., Morey, A.L., Lee, C.S., Kench, J.G., Biankin, S.A., Hook, H.C., Head, D.R., Hugh, T.B., Sutherland, R.L., and Henshall, S.M. 2002. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J. Clin. Oncol. 20: 4531-4542.
8. Bierie, B. and Moses, H.L. 2006. Tumour microenvironment: TGFβ: The molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 6: 506-520.
9. Bottinger, E.P., Jakubczak, J.L., Roberts, I.S., Mumy, M., Hemmati, P., Bagnall, K., Merlino, G., and Wakefield, L.M. 1997. Expression of a dominant-negative mutant TGF-β type II receptor in transgenic mice reveals essential roles for TGF-β in regulation of growth and differentiation in the exocrine pancreas. EMBO J. 16: 2621-2633.
10. Chu, G.C., Dunn, N.R., Anderson, D.C., Oxburgh, L., and Robertson, E.J. 2004. Differential requirements for Smad4 in TGFβ-dependent patterning of the early mouse embryo. Development 131: 3501-3512.
11. Dai, J.L., Schutte, M., Bansal, R.K., Wilentz, R.E., Sugar, A.Y., and Kern, S.E. 1999. Transforming growth factor-β responsiveness in DPC4/SMAD4-null cancer cells. Mol. Carcinog. 26: 37-43.
12. Duda, D.G., Sunamura, M., Lefter, L.P., Furukawa, T., Yokoyama, T., Yatsuoka, T., Abe, T., Inoue, H., Motoi, F., Egawa, S., et al. 2003. Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells. Oncogene 22: 6857-6864.
13. Ellenrieder, V., Hendler, S.F., Boeck, W., Seufferlein, T., Menke, A., Ruhland, C., Adler, G., and Gress, T.M. 2001. Transforming growth factor β1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res. 61: 4222-4228.
14. Friess, H., Yamanaka, Y., Buchler, M., Berger, H.G., Kobrin, M.S., Baldwin, R.L., and Korc, M. 1993a. Enhanced expression of the type II transforming growth factor β receptor in human pancreatic cancer cells without alteration of type III receptor expression. Cancer Res. 53: 2704-2707.
15. Friess, H., Yamanaka, Y., Buchler, M., Ebert, M., Beger, H.G., Gold, L.I., and Korc, M. 1993b. Enhanced expression of transforming growth factor β isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 105: 1846-1856.
16. Giehl, K., Seidel, B., Gierschik, P., Adler, G., and Menke, A. 2000. TGFβ1 represses proliferation of pancreatic carcinoma cells which correlates with Smad4-independent inhibition of ERK activation. Oncogene 19: 4531-4541.
17. Gu, G., Dubauskaite, J., and Melton, D.A. 2002. Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. Development 129: 2447-2457.
18. Hahm, K.B., Im, Y.H., Lee, C., Parks, W.T., Bang, Y.J., Green, J.E., and Kim, S.J. 2000. Loss of TGF-β signaling contributes to autoimmune pancreatitis. J. Clin. Invest. 105: 1057-1065.
19. Hahn, S.A., Schutte, M., Hoque, A.T., Moskaluk, C.A., da Costa, L.T., Rozenblum, E., Weinstein, C.L., Fischer, A., Yeo, C.J., Hruban, R.H., et al. 1996. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271: 350-353.
20. Hansel, D.E., Kern, S.E., and Hruban, R.H. 2003. Molecular pathogenesis of pancreatic cancer. Annu. Rev. Genomics Hum. Genet. 4: 237-256.
21. Harmon, E.B., Apelqvist, A.A., Smart, N.G., Gu, X., Osborne, D.H., and Kim, S.K. 2004. GDF11 modulates NGN3+ islet progenitor cell number and promotes β-cell differentiation in pancreas development. Development 131: 6163-6174.
22. He, W., Dorn, D.C., Erdjument-Bromage, H., Tempst, P., Moore, M.A., and Massague, J. 2006. Hematopoiesis controlled by distinct TIF1γ and Smad4 branches of the TGFβ pathway. Cell 125: 929-941.
23. Helfman, D.M., Kim, E.J., Lukanidin, E., and Grigorian, M. 2005. The metastasis associated protein S100A4: Role in tumour progression and metastasis. Br. J. Cancer 92: 1955-1958.
24. Hezel, A.F., Kimmelman, A.C., Stanger, B.Z., Bardeesy, N., and Depinho, R.A. 2006. Genetics and biology of pancreatic ductal adenocarcinoma. Genes & Dev. 20: 1218-1249.
25. Hingorani, S.R., Petricoin, E.F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M.A., Ross, S., Conrads, T.P., Veenstra, T.D., Hitt, B.A., et al. 2003. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4: 437-450.
26. Hingorani, S.R., Wang, L., Multani, A.S., Combs, C., Deramaudt, T.B., Hruban, R.H., Rustgi, A.K., Chang, S., and Tuveson, D.A. 2005. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7: 469-483.
27. Howe, J.R., Roth, S., Ringold, J.C., Summers, R.W., Jarvinen, H.J., Sistonen, P., Tomlinson, I.P., Houlston, R.S., Bevan, S., Mitros, F.A., et al. 1998. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 280: 1086-1088.
28. Howe, J.R., Bair, J.L., Sayed, M.G., Anderson, M.E., Mitros, F.A., Petersen, G.M., Velculescu, V.E., Traverso, G., and Vogelstein, B. 2001. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat. Genet. 28: 184-187.
29. Hruban, R.H., Adsay, N.V., Albores-Saavedra, J., Anver, M.R., Biankin, A.V., Boivin, G.P., Furth, E.E., Furukawa, T., Klein, A., Klimstra, D.S., et al. 2006. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: Consensus report and recommendations. Cancer Res. 66: 95-106.
30. Ito, D., Fujimoto, K., Doi, R., Koizumi, M., Toyoda, E., Mori, T., Kami, K., Kawaguchi, Y., Whitehead, R., and Imamura, M. 2004. Chronic exposure of transforming growth factor β1 confers a more aggressive tumor phenotype through downregulation of p21(WAF1/CIP1) in conditionally immortalized pancreatic epithelial cells. Surgery 136: 364-374.
31. Jonson, T., Heidenblad, M., Hakansson, P., Gorunova, L., Johansson, B., Fioretos, T., and Hoglund, M. 2003. Pancreatic carcinoma cell lines with SMAD4 inactivation show distinct expression responses to TGFB1. Genes Chromosomes Cancer 36: 340-352.
32. Jung, B., Doctolero, R.T., Tajima, A., Nguyen, A.K., Keku, T., Sandler, R.S., and Carethers, J.M. 2004. Loss of activin receptor type 2 protein expression in microsatellite unstable colon cancers. Gastroenterology 126: 654-659.
33. Kawaguchi, Y., Cooper, B., Gannon, M., Ray, M., MacDonald, R.J., and Wright, C.V. 2002. The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors. Nat. Genet. 32: 128-134.
34. Kim, S.K., Hebrok, M., Li, E., Oh, S.P., Schrewe, H., Harmon, E.B., Lee, J.S., and Melton, D.A. 2000. Activin receptor patterning of foregut organogenesis. Genes & Dev. 14: 1866-1871.
35. Li, W., Qiao, W., Chen, L., Xu, X., Yang, X., Li, D., Li, C., Brodie, S.G., Meguid, M.M., Hennighausen, L., et al. 2003. Squamous cell carcinoma and mammary abscess formation through squamous metaplasia in Smad4/Dpc4 conditional knockout mice. Development 130: 6143-6153.
36. Li, D., Xie, K., Wolff, R., and Abbruzzese, J.L. 2004. Pancreatic cancer. Lancet 363: 1049-1057.
37. Lohr, M., Schmidt, C., Ringel, J., Kluth, M., Muller, P., Nizze, H., and Jesnowski, R. 2001. Transforming growth factor-β1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Res. 61: 550-555.
38. Maitra, A., Fukushima, N., Takaori, K., and Hruban, R.H. 2005. Precursors to invasive pancreatic cancer. Adv. Anat. Pathol. 12: 81-91.
39. Moniaux, N., Andrianifahanana, M., Brand, R.E., and Batra, S.K. 2004. Multiple roles of mucins in pancreatic cancer, a lethal and challenging malignancy. Br. J. Cancer 91: 1633-1638.
40. Nicolas, F.J. and Hill, C.S. 2003. Attenuation of the TGF-β-Smad signaling pathway in pancreatic tumor cells confers resistance to TGF-β-induced growth arrest. Oncogene 22: 3698-3711.
41. Okada, H., Danoff, T.M., Kalluri, R., and Neilson, E.G. 1997. Early role of Fsp1 in epithelial-mesenchymal transformation. Am. J. Physiol. 273: F563-F574.
42. Peng, B., Fleming, J.B., Breslin, T., Grau, A.M., Fojioka, S., Abbruzzese, J.L., Evans, D.B., Ayers, D., Wathen, K., Wu, T., et al. 2002. Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells. Clin. Cancer Res. 8: 3628-3638.
43. Rodriguez, C.I., Buchholz, F., Galloway, J., Sequerra, R., Kasper, J., Ayala, R., Stewart, A.F., and Dymecki, S.M. 2000. High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP. Nat. Genet. 25: 139-140.
44. Rosty, C., Ueki, T., Argani, P., Jansen, M., Yeo, C.J., Cameron, J.L., Hruban, R.H., and Goggins, M. 2002. Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. Am. J. Pathol. 160: 45-50.
45. Rowland-Goldsmith, M.A., Maruyama, H., Kusama, T., Ralli, S., and Korc, M. 2001. Soluble type II transforming growth factor-β (TGF-β) receptor inhibits TGF-β signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation. Clin. Cancer Res. 7: 2931-2940.
46. Schwarte-Waldhoff, I., Volpert, O.V., Bouck, N.P., Sipos, B., Hahn, S.A., Klein-Scory, S., Luttges, J., Kloppel, G., Graeven, U., Eilert-Micus, C., et al. 2000. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc. Natl. Acad. Sci. 97: 9624-9629.
47. Simeone, D.M., Zhang, L., Treutelaar, M.K., Zhang, L., Graziano, K., Logsdon, C.D., and Burant, C.F. 2006. Islet hypertrophy following pancreatic disruption of smad4 signaling. Am. J. Physiol. Endocrinol. Metab. Epub May 30, 2006; doi: 10.1152/ajpendo.00561.2005.
48. Sipos, B., Moser, S., Kalthoff, H., Torok, V., Lohr, M., and Kloppel, G. 2003. A comprehensive characterization of pancreatic ductal carcinoma cell lines: Towards the establishment of an in vitro research platform. Virchows Arch. 442: 444-452.
49. Sirard, C., de la Pompa, J.L., Elia, A., Itie, A., Mirtsos, C., Cheung, A., Hahn, S., Wakeham, A., Schwartz, L., Kern, S.E., et al. 1998. The tumor suppressor gene Smad4/Dpc4 is required for gastrulation and later for anterior development of the mouse embryo. Genes & Dev. 12: 107-119.
50. Smart, N.G., Apelqvist, A.A., Gu, X., Harmon, E.B., Topper, J.N., MacDonald, R.J., and Kim, S.K. 2006. Conditional expression of Smad7 in pancreatic β cells disrupts TGF-β signaling and induces reversible diabetes mellitus. PLoS Biol. 4: e39.
51. Solcia, E., Capella, C., and Kloppel, G. 1995. Tumors of the pancreas. Armed Forces Institute for Pathology, Washington, DC.
52. Subramanian, G., Schwarz, R.E., Higgins, L., McEnroe, G., Chakravarty, S., Dugar, S., and Reiss, M. 2004. Targeting endogenous transforming growth factor β receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1. Cancer Res. 64: 5200-5211.
53. Takaku, K., Miyoshi, H., Matsunaga, A., Oshima, M., Sasaki, N., and Taketo, M.M. 1999. Gastric and duodenal polyps in Smad4 (Dpc4) knockout mice. Cancer Res. 59: 6113-6117.
54. Tascilar, M., Skinner, H.G., Rosty, C., Sohn, T., Wilentz, R.E., Offerhaus, G.J., Adsay, V., Abrams, R.A., Cameron, J.L., Kern, S.E., et al. 2001. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin. Cancer Res. 7: 4115-4121.
55. Venkatasubbarao, K., Ahmed, M.M., Swiderski, C., Harp, C., Lee, E.Y., McGrath, P., Mohiuddin, M., Strodel, W., and Freeman, J.W. 1998. Novel mutations in the polyadenine tract of the transforming growth factor β type II receptor gene are found in a subpopulation of human pancreatic adenocarcinomas. Genes Chromosomes Cancer 22: 138-144.
56. Wagner, M., Kleeff, J., Friess, H., Buchler, M.W., and Korc, M. 1999. Enhanced expression of the type II transforming growth factor-β receptor is associated with decreased survival in human pancreatic cancer. Pancreas 19: 370-376.
57. Wang, R.H., Li, C., Xu, X., Zheng, Y., Xiao, C., Zerfas, P., Cooperman, S., Eckhaus, M., Rouault, T., Mishra, L., et al. 2005. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab. 2: 399-409.
58. Wilentz, R.E., Goggins, M., Redston, M., Marcus, V.A., Adsay, N.V., Sohn, T.A., Kadkol, S.S., Yeo, C.J., Choti, M., Zahurak, M., et al. 2000. Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity. Am. J. Pathol. 156: 1641-1651.
59. Yang, X., Li, C., Xu, X., and Deng, C. 1998. The tumor suppressor SMAD4/DPC4 is essential for epiblast proliferation and mesoderm induction in mice. Proc. Natl. Acad. Sci. 95: 3667-3672.
60. Zavadil, J. and Bottinger, E.P. 2005. TGF-β and epithelial-to- mesenchymal transitions. Oncogene 24: 5764-5774.